LDS/Medical Tests/Hepatitis Be Antigen

Hepatitis Be Antigen

Hepatitis B infection is caused by the Hepatitis B virus and is responsible for mortality everywhere in the world. Hepatitis B virus is spread by contact with contaminated blood and body fluids. Chronic infection with Hepatitis B virus results in damage to the liver, ultimately resulting in liver disease, cirrhosis, and/or liver cancer. The body’s immune system is responsible for the liver tissue damage since it destroys the liver cells containing the virus. Consumption of alcohol during infection with Hepatitis B virus is discouraged as it can increase the damage to the liver. Hepatitis B virus is prevented by cautious and safe handling of blood or body fluids and also by vaccination. Serology testing to detect hepatitis B surface antigen is the standard for diagnosing the disease. However, progression of the disease and the treatment of the disease could be monitored by testing for HBe antigen (HBeAg).

HBeAg first appears shortly after the appearance of HBsAg, and then disappears before HBsAg in recovering patients. In chronic infections this marker is usually present during periods of active replication, and indicates a high degree of infectivity. HBeAg is a soluble protein secreted by HBV, related to HBcAg, indicating viral replication and infectivity. Two distinct serologic types of hepatitis B have been described, one with a positive HBeAg and the other with a negative HBeAg and a positive anti-HBe antibody (HBeAb). The assumption has been that loss of HBeAg and accumulation of HBeAb are associated with decreased infectivity. Testing has proved unreliable, and tests are not routinely needed as indicators of infectivity. Since all patients positive for HBsAg must be considered infectious, the best test to confirm infection is HBV DNA or viral load.

  • Diagnosis of acute HBV infection
  • Differential diagnosis between acute and chronic HBV infections
  • Determine if HBV infection is in non-replicating state

Positive in:

  • Active HBV infection
  • Relapsing infection (unsuccessful treatment)

Negative (Non-reactive)

Enzyme immunoassay, Chemiluminescence immunoassay.

Serum (SST), Plasma (EDTA). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
HBsAg, HBV Viral load, Liver Panel, Acute Hepatitis Panel, Lactate Dehydrogenase, Liver Biopsy.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Hepat Mon. 2011 May 1;11(5):351-7. [PMID: 22087160]
  • Cochrane Database Syst Rev. 2002;2:CD000345. [PMID: 12076393]
  • Clin Liver Dis. 2004;8:267. [PMID: 15481340]
  • Gastroenterol Clin Biol. 2008 Jan;32(1 Pt 2):S56-63. [PMID: 18662611]
  • N Engl J Med. 2004 Mar 11;350(11):1118-29. [PMID: 15014185]
  • Stevens, CD. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company (2010).
  • Burtis C, Ashwood E, and Bruns D. Fundamentals of Clinical Chemistry. St. Louis: Saunders (2008).